(19)
(11) EP 4 277 612 A1

(12)

(43) Date of publication:
22.11.2023 Bulletin 2023/47

(21) Application number: 22740224.5

(22) Date of filing: 18.01.2022
(51) International Patent Classification (IPC): 
A61K 31/137(2006.01)
A61P 25/24(2006.01)
 A61K 31/485(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/137; A61P 25/24; A61K 31/485; A61K 45/06
 
C-Sets:
  1. A61K 31/485, A61K 2300/00;
  2. A61K 31/137, A61K 2300/00;
(86) International application number:
PCT/US2022/012768
(87) International publication number:
WO 2022/155591 (21.07.2022 Gazette 2022/29)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 18.01.2021 US 202163138757 P

(71) Applicant: Antecip Bioventures II LLC
New York, NY 10111 (US)

(72) Inventor:
  • TABUTEAU, Herriot
    New York, NY 10007 (US)

(74) Representative: Murgitroyd & Company 
Murgitroyd House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)

   


(54) COMBINATION OF AN ANTIDEPRESSANT AND DEXTROMETHORPHAN FOR NEUROPSYCHIATRIC CONDITIONS